Taiwan drugmakers embrace China's speedy approval policies

China’s Food and Drug Administration recently issued many new polices to push healthcare reform and drug innovation in the country. One of them is to acknowledge foreign trial data and hire more staff to speed up Investigational New Drug (IND) and New Drug Applications (NDA) approval, writes The Pharma Letter’s China correspondent Wang Fangqing.

Such a change no doubt encourages foreign companies to introduce novel drugs to the Chinese market, the world’s second largest drug market just behind the USA.

Taiwan drugmakers, which currently have a marginal market share in the mainland China, see the new polices as a great opportunity to grow sales in the mainland.